Condition
Obese Diabetics
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownRemission of Type 2 Diabetes With Lifestyle InterventionNCT07017127 · 2025-05-01
RECRUITINGComparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialNCT07820111 · 2025-10-18
COMPLETEDThe Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and ObesityNCT07120828 · 2025-07-15
COMPLETEDIn Vivo Leptin Signaling in Humans After Acute Leptin AdministrationNCT01275053 · 2002-07-01
COMPLETEDCommon interventions
Dapagliflozin (DAPA)DRUG1Dulaglutide 0.75mg subcutaneous injectionDRUG1Dulaglutide 1.5 MG/MLDRUG1Empagliflozin (oral)DRUG1leptinDRUG1Mediterranean dietBEHAVIORAL1MetfominDRUG1Physical activity interventionBEHAVIORAL1Psychological interventionBEHAVIORAL1Semaglutide 1.0 mgDRUG1Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solutionDRUG1Tirzepatide (Flexible titration)DRUG1Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physicianDRUG1
Leading sponsors
Trial status mix
COMPLETED3
RECRUITING1
Phase mix
NA1
PHASE11
PHASE31
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.